secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001104659-25-023447
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin reports FY2024 net loss $9.0M; cash $14.1M; positive QRX003 whole-body data in Netherton
--------------------------------------------------------------------------------

- Cash of $14.1M at Dec 31, 2024 expected to fund operations into Q2 2026.
- Net loss FY2024 $9.0M vs $8.7M; Q4 loss $2.3M vs $2.0M year ago.
- First pediatric patient on whole-body QRX003 showed skin healing in 2 weeks, discontinued all prior meds, zero sleep disturbances.
- FDA cleared whole-body QRX003 study; to be led by Dr. Amy Paller at Northwestern University.
- Filed patent applications for topical rapamycin formulations targeting rare dermatological diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925023447/0001104659-25-023447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925023447/tm259112d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-023447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer